Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.

Perry Elliott,Brian M Drachman,Stephen S Gottlieb,James E Hoffman,Scott L Hummel,Daniel J Lenihan,Ben Ebede,Balarama Gundapaneni,Benjamin Li,Marla B Sultan,Sanjiv J Shah

Future cardiology（2023）

Cited 0|Views53

No score

Abstract

Taking tafamidis increases how long people with ATTR-CM live. People with ATTR-CM who take tafamidis early and continuously are more likely to live longer than those who do not. These results highlight the importance of early detection and treatment in people with ATTR-CM. : NCT01994889 (ClinicalTrials.gov) : NCT02791230 (ClinicalTrials.gov).

Translated text

Key words

amyloidosis,cardiomyopathy,heart failure,lay summary,plain language summary,quality of life,tafamidis,transthyretin

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined